Introduction: Early allograft dysfunction (EAD) remains one of the most important early indicators of graft performance after liver transplantation. Traditionally, EAD has been defined using biochemical parameters developed largely from deceased donor liver transplantation populations.
Introduction:
Early allograft dysfunction (EAD) remains one of the most important early indicators of graft performance after liver transplantation. Traditionally, EAD has been defined using biochemical parameters developed largely from deceased donor liver transplantation populations. However, living donor liver transplantation (LDLT) presents unique physiological and surgical characteristics, including smaller graft volumes, regenerative dynamics, and distinct perioperative factors, which may limit the applicability of conventional EAD definitions.
Problem Statement:
Current EAD models may not accurately reflect graft function or predict outcomes in LDLT recipients. Reliance on static biochemical thresholds can oversimplify the complex and evolving process of graft recovery, potentially leading to inaccurate risk stratification and delayed recognition of clinically significant dysfunction. There is an increasing need for more precise, individualized, and clinically meaningful approaches tailored specifically to LDLT.
Summary:
This editorial highlights the need to move beyond traditional definitions of EAD and adopt a more adaptive framework for assessing graft function following LDLT. The authors emphasize that graft recovery is a dynamic process influenced by donor characteristics, graft size, recipient factors, surgical complexity, and postoperative regenerative capacity. Rather than depending solely on fixed laboratory cut-offs, future models should incorporate longitudinal clinical and biochemical trends to better capture the evolving nature of graft performance. The article also underscores the growing potential of artificial intelligence and machine-learning technologies to integrate large volumes of perioperative and postoperative data, enabling more accurate prediction of graft dysfunction and patient outcomes. Such data-driven approaches could facilitate earlier intervention, personalized monitoring, and improved clinical decision-making. As LDLT continues to expand globally, the development of graft-specific and AI-enabled assessment tools may represent a significant step toward precision transplantation, offering a more nuanced understanding of early graft recovery and ultimately improving transplant outcomes.
Introduction: Bacterial infections remain a major cause of morbidity after liver transplantation despite advances in perioperative care. Synbiotics, combining probiotics and prebiotics, have been proposed to reduce postoperative infections by restoring gut microbiota and strengthening...
Introduction: Perioperative bleeding remains a major challenge during orthotopic liver transplantation (OLT), largely due to hyperfibrinolysis and coagulation abnormalities. Although tranexamic acid (TXA) effectively reduces bleeding in several surgical settings, its routine prophylactic use during...
Introduction: Liver transplantation is limited by a shortage of suitable donor organs. Current viability assessment relies on needle biopsy, which samples only a small portion of the liver and may miss important regional pathology. This...
Introduction: Bleeding remains a major challenge during liver transplantation despite advances in surgical techniques, anesthesia, and perioperative care. Antifibrinolytic agents have long been used to reduce intraoperative blood loss and transfusion requirements. However, evolving transplant...
Introduction: The demand for liver transplantation continues to exceed the availability of deceased donor organs, resulting in prolonged waiting times and preventable waitlist mortality. This perspective discusses how living donor liver transplantation (LDLT) can complement...
Introduction: Pediatric liver transplantation has achieved excellent survival rates, shifting the focus from graft survival alone to optimising long-term health, growth, neurodevelopment, and quality of life. This updated guideline provides evidence-based recommendations for comprehensive care...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.